Skip Ribbon Commands
Skip to main content


The Epidemiology, Modeling and Trial Designs Community is comprised of individuals from different Institutions worldwide and includes the following members:​​

Dr Frank ​Cobelens


Frank Cobelens is professor of Global Health at the University of Amsterdam, The Netherlands. His scientific interest is multidisciplinary approaches to problems on the interface of biomedical aspects of infectious diseases (notably tuberculosis), their socioeconomic context and public health policy, as well as in evaluation of control interventions. ​

Dr Richard White


Richard White is a Prof of Infectious Disease Modelling at LSHTM. His research focus is the mathematical and statistical modelling of the transmission and control of infectious diseases, particularly TB and HIV. He is Director of the TB Modelling and Analysis Consortium, and co-leads the LSHTM TB Modelling Group.


Dr Lele Rangaka

Dr. Rangaka is a Clinical Associate Professor within the Institute of Global Health, University College London (UCL), United Kingdom. She is also affiliated to the MRC Clinical Trials Unit at UCL and is an honorary Associate Professor at the University of Cape Town (UCT), South Africa. She is an Infectious Disease Clinical Scientist with >15 years experience, her research areas span HIV/TB epidemiology, randomized assessments of public health technology, digital health innovation and implementation science. She conducts clinical trials of TB prevention focusing integrating biomedical and non-biomedical strategies across multimorbidities, innovation in adherence monitoring, diagnostics and m-health innovation.


Dr Marcel Behr

Dr. Behr is a clinician-scientist with appointments of Full Professor in the Department of Medicine and Associate member in the departments of Epidemiology and Biostatistics as well as Microbiology and Immunology. He is the founding Director of the McGill International TB Centre and led it from 2012 to 2018. He is the Associate Program Leader of the Infectious Diseases and Immunity in Global Health Program at the Research Institute of the McGill University Health Centre since 2016 and in 2017 he became the co-Director the McGill Interdisciplinary Initiative in Infection and Immunity (McGill-i4). He is the interim director of McGill Infectious Diseases Division.

Dr. Behr trained at the University of Toronto, Queen’s, McGill and Stanford. His work has been recognized by election into the Canadian Academy of Health Sciences, the Royal Society of Canada, the American Society for Clinical Investigation and the American Academy of Microbiology. Dr. Behr’s lab uses bacterial genomic methodologies to study the epidemiology and pathogenesis of tuberculosis and other mycobacterial diseases.


Dr Gavin Churchyard

Prof Churchyard (MBBCh, MMED (Int Med), FCP (SA), FRCP (Edin), PhD) is a specialist physician, internationally renowned for his contributions in tuberculosis (TB) research. Prof Churchyard is the founder and Group Chief Executive Officer of the Aurum Institute, an independent, not for profit, proudly South African, public benefit organization that focuses on TB and HIV technical assistance, service delivery, and research. Prof Churchyard is an Honorary Professor at the University of Witwatersrand and University of Cape Town. Prof Churchyard is the Chair of the AIDS Clinical Trials Group (ACTG) Transformative Science Group for TB, Chair of the Cross-Network TB vaccine Working Group and a member of the ACTG New Chemical Entities Working Group. He has extensive clinical trials experience and has conducted numerous TB treatment, TB vaccine, TB preventive therapy, TB diagnostics and Host Directed Therapy for TB trials.


Dr Tom Evans

Dr Evans received his MD in 1983, and trained in Internal Medicine and Infectious Diseases. He directed the HIV clinic at the University of Utah, was Associate Professor at University of Rochester, and tenured Professor and Infectious Diseases Chief University of California, Davis. He held positions as CMO at Vical, Global Head of Infectious Diseases Translational Medicine and Research for Novartis, CSO/CEO for Aeras, CMO for Tomegavax, and CEO of Vaccitech in Oxford. He has over 160 authored publications.


Dr Andrew Fiore-Gartland

Dr Mike Frick

Mike Frick is one of the co-directors of TAG’s tuberculosis program. He leads the following areas of TAG’s TB portfolio: 1) advocacy to support universal access to TB prevention, including research to develop new TB vaccines and preventive therapies; 2) research to track global funding for TB research and development; and 3) work to define and apply the human right to enjoy the benefits of scientific progress to advance TB research and access. Mike holds a BA in international studies from Kenyon College and an MSc in global health and population from the Harvard T.H. Chan School of Public Health.

Dr Alberto Garcia-Basteiro

Dr Alberto Garcia-Basteiro currently coordinates the TB research unit at the Centro de Investigação em Saúde de Manhiça (CISM), Mozambique. He was trained as a physician at University of Santiago de Compostela (USC), Spain, and completed the residency on preventative medicine and public health at Hospital Clinic in Barcelona, a Master´s Degree of Epidemiology from the London School of Hygiene and Tropical Medicine (LSHTM) and a PhD at Amsterdam University. He has participated in different research projects and clinical trials in poverty related diseases. Since June 2012, he is affiliated with the Barcelona Institute for Global Health (ISGlobal). The TB research area at CISM is involved in several large observational studies and clinical trials which contribute to the development of new tools to fight tuberculosis, including new drugs, new vaccines and new diagnostic tools. Dr Garcia-Basteiro’s interests include the study of the burden of TB disease in different vulnerable populations and characterization of the disease at clinical, microbiological and social level.

Dr Rebecca Harris

Dr Mark Hatherill

Professor Mark Hatherill is Director and leader of the clinical research team of the South African Tuberculosis Vaccine Initiative (SATVI), a University of Cape Town research group focused on understanding risk for and protection against TB, to develop better vaccines and therapies that will impact the global epidemic. A University of Cape Town medical graduate, he trained as a pediatrician and critical care sub-specialist. He has been involved with 28 clinical trials of 9 novel TB vaccine candidates conducted at the SATVI research site near Cape Town, in parallel with large epidemiological and immunological cohort studies. Prof Hatherill has played a lead role in pivotal efficacy trials that have tested the candidate vaccine MVA85A for prevention of TB disease in infants; BCG revaccination for prevention of M. tuberculosis infection in adolescents; and the candidate vaccine M72/ASO1E for prevention of TB disease in adults. He is Co-Chair of the Regional Prospective Observational Research in Tuberculosis (RePORT) South Africa consortium. His current work focuses on the design and implementation of clinical trials of novel TB vaccines and biomarker-targeted TB prevention.

Dr Philip Hill

Professor Philip Hill is a medical practitioner, specialist public health physician, specialist infectious diseases physician, and has a doctorate in the epidemiology of tuberculosis. After completing specialty training in New Zealand, he spent 6 years working as a clinical epidemiologist at the Medical Research Council (UK) research unit in The Gambia, working on tuberculosis (TB) and pneumonia projects. Professor Hill is the first holder of the McAuley Chair in International Health and is Founding Director and Co-Director of the Centre for International Health at the University of Otago. He is involved in research projects in Africa, Asia, Europe, South America and the Pacific. In 2008 Professor Hill established the Otago Global Health Institute of over 100 researchers across all four divisions of the University, with an interest in health research in low-and middle-income countries. The Otago Global Health Institute is one of 12 flagship research centres of the University. He is currently Co-Director of the Institute. Professor Hill has a special interest in training people from low- and middle-income countries at masters’ and PhD level, with a view to them becoming internationally competitive academic leaders back in their home country. 

Dr Robin Mogg

Dr Videlis Nduba

Dr Matthew Quaife

I am a health economist working on understanding the cost-effectiveness and equity impact of interventions to prevent infectious disease, including TB. Most of my work is at the interface of health economics and infectious disease modelling, understanding risk and prevention behaviours and how they cluster in different populations.

Dr Alexander Schmidt

Dr Dereck Tait​

Dr Tait, who qualified in medicine and subsequently specialized in medical microbiology and virology, has spent more than 20 years in clinical development leading clinical development programmes. These have predominantly been for compounds or biologics for the treatment and prevention of infectious diseases, including those where the burden of disease is primarily in low and middle-income countries. Over the last 8 years he has been involved in the development of TB vaccines and during this time has been involved in the clinical development of a number of candidate TB vaccines.